Stockreport

How The Travere Therapeutics (TVTX) Story Is Shifting After FSGS Approval And Split Analyst Views [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF Travere Therapeutics just saw its modeled fair value per share move slightly, from US$42.36 to US$42.50, in the latest analyst update. That modest shift sits against a [Read more]